Business Context and Reporting Period
Company: Sunshine Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 21, 2023
Principal Executive Offices: Pointe-Claire, Quebec, Canada
Listing: The Nasdaq Capital Market (Common Stock: SBFM; Warrants: SBFMW)
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material event reported is the Company's receipt of a notification from The Nasdaq Stock Market LLC regarding its compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- Deficiency: The closing bid price for the Company's common stock was below $1.00 for 30 consecutive trading days.
- Previous Notification: Initially notified on March 24, 2023.
- Current Status: On September 21, 2023, Nasdaq staff determined the Company is eligible for an additional 180-calendar-day extension to cure the deficiency.
- Compliance Deadline: March 18, 2024.
Guidance, Outlook, and Risks
Management Commentary and Plan: The Company intends to actively monitor the bid price of its common stock through March 18, 2024. Management stated it will consider all available options to resolve the deficiency, including effecting a reverse stock split if necessary.
Compliance Criteria: To regain compliance before the deadline, the bid price must close at or above $1.00 per share for a minimum of 10 consecutive business days.
Risks and Contingencies: If the Company fails to regain compliance by March 18, 2024, it risks delisting from The Nasdaq Capital Market. The notification has no immediate effect on the current listing status.
Investor Verification Checklist
- Verify the current trading price of SBFM to assess proximity to the $1.00 threshold.
- Monitor future press releases or filings for announcements regarding a potential reverse stock split.
- Confirm the Company's continued compliance with other Nasdaq listing requirements (e.g., market value of publicly held shares).
- Review the attached Exhibit 99.1 (Press Release) for additional details on the Company's specific remediation strategy.